
Dr. Fabbri Alessandra
Doctor
Contacts
- Mail: Alessandra.fabbri@istitutotumori.mi.it
- Tel: 0223903216
Specialty / Department
- Anatomic Pathology
An accomplished Medical Doctor specializing in Anatomic Pathology, bringing extensive experience gained at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, where she has dedicated her career since 1997. She earned her degree in Medicine and Surgery from the University of Pavia in 1992, achieving professional qualification that same year, followed by specialization in 1996. With the exception of a brief period, her professional journey has been consistently within the Department of Anatomic Pathology, collaborating with notable directors such as Prof. Pilotti, Prof. Rosai, and the current director, Prof. Pruneri. Her primary professional focus is on the oncological diagnosis of thoracic malignancies, including lung and thymus cancers.
Her core competencies include sophisticated histopathological diagnosis, precise intraoperative consultations, meticulous tissue sampling, and expert case review in challenging clinical scenarios. Her active participation in the multidisciplinary Thoracic Oncology group underscores her key role in the diagnostic evaluation process. She also actively contributes to interdisciplinary scientific discourse within the field of surgical pathology.
Possessing solid experience in the execution of clinical trials in full compliance with GCP standards and demonstrating proficiency in relevant digital technologies, she has authored scientific publications in high-impact peer-reviewed journals. Her language skills include fluency in English and French.
Demonstrating leadership and commitment to quality, she holds the positions of Quality Officer and appointed Safety Manager for the Department. Additionally, she contributes her expertise as a member of the Committee Responsible for the Assessment of Health Technology Assessment (HTA) Processes for Health Technologies Alessandra Fabbri MD
MicroRNA circolanti per scegliere la strategia immunoterapica nei pazienti con NSCLC
PD-L1≥50%: studio clinico ArK -BRI
Pz con NSCLC avanzato( IIIC/IV) con PDL1>= 50 % non trattato , no mutazioni, analisi miRNA.
PI dr.ssa Proto
EPIGENETICS IN SCLC TO EARLY DETECT TREATMENT RESISTANCE AND DISCOVERY NEW DRUGGABLE PATHWAYS.
Principal Investigator: Teresa Beninato (LineaI)
Co-Principal Investigator: Alessandra Fabbri
Gruppo ricerca mesoteliomi MET.I
Modello evoluto di gestione digitale del percorso Polmone
In collaborazione con il Politecnico di Milano e MSD (MERK).
Obiettivo: analizzare e revisionare i processi organizzativi gestionali, introducendo nuovi modelli e soluzioni digitali come la TELEMEDICINA
- Mail: Alessandra.fabbri@istitutotumori.mi.it
- Tel: 0223903216
Anatomia patologica 2
Last update: 03/06/2025